Breast cancer (invasive) · line 1 · AI + palbociclib (HR+/HER2- metastatic 1L)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-AI-PALBOCICLIB`

ID	`IND-BREAST-HR-POS-MAINT-CDK46I`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-BREAST`
Sources	`SRC-ESMO-BREAST-METASTATIC-2024` `SRC-MONALEESA-2-HORTOBAGYI-2016` `SRC-MONARCH-3-GOETZ-2017` `SRC-NCCN-BREAST-2025` `SRC-PALOMA-2-FINN-2016`

Notes

STUB — pending Clinical Co-Lead sign-off. line_of_therapy: 1 because CDK4/6i + AI continuation is the 1L pathway. Engine activates this indication for any patient on CDK4/6i + AI 1L beyond first restaging.

Used By

No reverse references found in the YAML corpus.